Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia (NCT07467993)
A Phase 2a, Randomized, Participant- and Investigator- Blinded, Parallel-group, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With DSM-5 Schizophrenia (STAR-1)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to assess the efficacy, safety, and tolerability of GXV813 in the treatment of an acute episode of schizophrenia
Who can join: Review the eligibility criteria below.
Location: Pillar Clinical Research LLC — Bentonville, Arkansas
Age range: 18 Years to 65 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (16 Sites)
- Pillar Clinical Research LLC — Bentonville, Arkansas
- CNRI Los Angeles LLC — Pico Rivera, California
- Segal Institute for Clinical Research — Miami, Florida
- CenExel iResearch — Decatur, Georgia
- Uptown Research Institute LLC — Chicago, Illinois
- Pillar Clinical Research LLC — Chicago, Illinois
- Arch Clinical Trials LLC — St Louis, Missouri
- Novartis Investigative Site — Sofia, BGR
- Novartis Investigative Site — Haskovo,
- Novartis Investigative Site — Kazanlak,
- Novartis Investigative Site — Lovech,
- Novartis Investigative Site — Plovdiv,
- Novartis Investigative Site — Sliven,
- Novartis Investigative Site — Sofia,
- Novartis Investigative Site — Veliko Tarnovo,
- Novartis Investigative Site — Vratsa,
📞 Contact the Study Coordinator
Phone: (888) 669-6682
Email: novartis.email@novartis.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Schizophrenia
- Young Adults With Violent Behavior During Early Psychosis (Aim 2) — New York, New York
- Does tDCS Change Synaptic Density in the Brains of Patients With Schizophrenia — Toronto, Ontario
- Ketogenic Diet in People With Schizophrenia — Catonsville, Maryland
- Paired Associative Stimulation in the Dorsolateral Prefrontal Cortex in Patients With Schizophrenia — Toronto, Ontario
- Investigating the Muscarinic System in Schizophrenia Using Positron Emission Tomography — Toronto, Ontario
- Long-Term Real-World Safety of Cobenfy in Adults With Schizophrenia — Suwanee, Georgia
Explore by condition: All Schizophrenia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.